TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07024615: A Phase 1b Study of Neoadjuvant ASP2138 Monotherapy and Investigator's Choice of Adjuvant Chemotherapy in Participants With Resectable Pancreatic Ductal Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression

Sponsor: Astellas Pharma Global Development, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 25 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$6,911,520

Rescue Site Savings

+$4,555,320

Unlock Full NCT07024615 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07024615 Rescue Dossier →